Abstracts Archive - Page 579 of 2607 - ACR Meeting Abstracts

Abstract Number: 1430 • ACR Convergence 2022
Time to First Remission and Prevalence of Sustained Remission After Etanercept Biosimilar (ETA-B) or Originator (ETA-O) Initiation in Rheumatoid Arthritis
Cristiano Moura¹, Luck Lukusa¹, Laura Yan¹, Walter P Maksymowych², Denis Choquette³, Gilles Boire⁴ and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁴Universite de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: The first biosimilar etanercept (ETA-B) was approved in Canada in 2016, but real-world data comparing the effectiveness of ETA-B versus its equivalent originator (ETA-O)…
Abstract Number: 1443 • ACR Convergence 2022
Lymphadenopathy in Systemic Lupus Erythematosus: Clinical Characteristics and Prognostic Features
Eleni Papachristodoulou, Daniel Magliulo and Vasileios Kyttaris, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Patients with SLE often develop lymphadenopathy (LAD), regarded as a relatively common manifestation of the disease. Its clinical significance has not yet been elucidated.…
Abstract Number: 1444 • ACR Convergence 2022
Patients with Lupus Pericarditis Have the Impact on the Poor Survival Outcome: A Retrospective Cohort Study
YENFU CHEN and Yao-Fan Fang, Chang Gung Memorial Hospital, Taoyuan, Taiwan
Background/Purpose: Patients with systemic lupus erythematosus (SLE) had a higher risk of pericarditis, which could be life-threating, but there has been no research focusing on…
Abstract Number: 1433 • ACR Convergence 2022
A 48-week Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Ulf Müller-Ladner¹, Karl Gaffney², Deepak Jadon³, Marco Matucci-Cerinic⁴, Eugenio Chamizo Carmona⁵ and Janet Addison⁶, ¹JLU Campus KK, Bad Nauheim, Germany, ²Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, ³Cambridge University, Cambridge, United Kingdom, ⁴University of Florence, Florence, Italy, ⁵Hospital de Mérida, Mérida, Spain, ⁶Biogen Idec Ltd, Maidenhead, United Kingdom
Background/Purpose: SB5, a biosimilar to reference adalimumab (ADL), received marketing authorisation in 2017 (EU) and 2019 (US) based on pre-clinical and clinical phase I and…
Abstract Number: 1442 • ACR Convergence 2022
Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus
Anca Askanase¹, John Conklin², Michelle Petri³, Vasileios Kyttaris⁴, Yevgeniya Gartshteyn⁵, Wei Tang¹, Anja Kammesheidt⁶ and Roberta Alexander², ¹Columbia University Medical Center, New York, NY, ²Exagen, Inc., Vista, CA, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁴Beth Israel Deaconess Medical Center, Boston, MA, ⁵Columbia University Medical Center, Glen Rock, NJ, ⁶self, Laguna Beach, CA
Background/Purpose: Platelet-bound complement activation products (PC4d) are associated with a history of thrombosis in systemic lupus erythematosus (SLE) (Gartshteyn al., 2021; Petri et al., 2017).…
Abstract Number: 1455 • ACR Convergence 2022
Immune Thrombocytopenic Purpura and Subsequent Development of Systemic Lupus Erythematosus
Gelsomina Alle¹, Marina Scolnik¹, VALERIA SCAGLIONI¹, John Fredy Jaramillo Gallego¹, Mayra Alejandra Tobar Jaramillo¹, Rodolfo Alvarado¹, Enrique R Soriano² and Javier Eduardo Rosa¹, ¹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: The aim of this study is to assess the incidence of Systemic Lupus Erythematosus (SLE) in a cohort of patients with Immune Thrombocytopenic Purpura…
Abstract Number: 1449 • ACR Convergence 2022
Incidence and Risk Factors for Active Tuberculosis in Patients with Systemic Lupus Erythematosus: A Multicenter Prospective Cohort Study
Lifan Zhang¹, xiaoqing zou², Lantian Xie³, Jianghao Liu³, zhengrong yang⁴, qifei cao⁴, Chunlei Li⁵, Xiaochuan Sun⁵, Fengchun ZHANG⁶, Yan Zhao⁷, Xiaofeng Zeng⁸ and Xiaoqing Liu¹, ¹Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Clinical Epidemiology Unit, Peking Union Medical College, International Clinical Epidemiology Network; Center for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China, ⁴Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁵Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁶Peking Union Medical College Hospital, Beijing, China, ⁷Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China, ⁸Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: The burden of tuberculosis (TB) and systemic lupus erythematosus (SLE) in China are both the second largest in the world. Patients with SLE are…
Abstract Number: 1451 • ACR Convergence 2022
Delayed Sleep Phase Syndrome Characterizes Circadian Disorder in Patients with Active SLE
Christina Stankey¹, Philip Chu², Alicia Hinze³, Lily McMorrow¹, Alia El-Qunni¹, Deepali Sen¹, Seth Eisen¹, Yo-El Ju¹ and Alfred Kim¹, ¹Washington University School of Medicine, St. Louis, MO, ²Duke University Hospital, Raleigh, NC, ³Mayo Clinic - Rochester, MN, Rochester, MN
Background/Purpose: Poor sleep quality is a common complaint of patients with SLE. Although chronic sleep disruption is known to drive circadian rhythm disorders, the effects…
Abstract Number: 1447 • ACR Convergence 2022
Serum Cytokine Profiling Reveals Elevated Levels of S100A8/A9 and MMP-9 in Systemic Lupus Erythematosus Patients with Cognitive Impairment Independently of Disease Activity and Inflammatory Markers
Carolina Munoz¹, Michelle Barraclough², Juan Pablo Diaz-Martinez¹, Jiandong Su¹, Kathleen Bingham³, Mahta Kakvan¹, Maria Carmela Tartaglia⁴, Leslet Ruttan⁵, May Choi⁶, Dennisse Bonilla¹, Simone Appenzeller⁷, Patricia Katz⁸, Dorcas Beaton⁹, Robin Green⁵, Joan Wither¹⁰ and Zahi Touma¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada, ³Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, ⁵University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁶Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁷Unicamp, Campinas, São Paulo, Brazil, ⁸UCSF, San Rafael, CA, ⁹Institute for Work & Health, Toronto, ON, Canada, ¹⁰Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is one of the most common manifestations of neuropsychiatric lupus(NPSLE), which may occur in the absence of active Systemic Lupus Erythematosus…
Abstract Number: 1458 • ACR Convergence 2022
Systemic Lupus Erythematosus (SLE) Patients with Cognitive Impairment Experience More Fatigue Compared to Patients Without Impairment
Delansie Lawrence¹, Jiandong Su¹, Andrea Knight², Kathleen Bingham³, Mahta Kakvan¹, Maria Carmela Tartaglia⁴, Leslet Ruttan⁵, Joan Wither⁶, May Choi⁷, Simone Appenzeller⁸, Nicole Anderson¹, Dennisse Bonilla¹, Patricia Katz⁹, Dorcas Beaton¹⁰, Robin Green⁵, Zahi Touma¹ and Michelle Barraclough¹¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, ⁵University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ⁷Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁸Unicamp, Campinas, São Paulo, Brazil, ⁹UCSF, San Rafael, CA, ¹⁰Institute for Work & Health, Toronto, ON, Canada, ¹¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is highly prevalent in patients with systemic lupus erythematosus (SLE). Objective prevalence rates are reported as 38% [range: 20% to 80%]…
Abstract Number: 1457 • ACR Convergence 2022
Baseline Characteristics of a Longitudinal, Multinational, Multiethnic Study of Lupus Patients, with or Without Lupus Nephritis
Romina Nieto¹, Rosana Quintana², eduardo Borba³, Lucia Hernandez⁴, Diana Fernandez-Avila⁵, Laura Maurelli⁶, Paul Alba⁷, Florencia Bordon⁸, Fernando Arizpe⁹, Guillermo Berbotta¹⁰, Rosa Serrano-Morales¹¹, Maria Constanza Bertolaccini¹², Eduardo Kerzberg¹³, Maria Angeles Gargiulo¹⁴, Anabella Rodriguez¹⁵, Vitalina Barbosa¹⁶, Andres gasparin¹⁷, Fernando Cavalcanti¹⁸, Laissa Alves Alvino¹⁹, Luciana Parente Costa Seguro²⁰, Lucas Victoria de Oliveira Martins²¹, oscar Niera²², Loreto Massardo²³, Gustavo Aroca Martinez²⁴, Ivana Nieto Aristizabal²⁵, Paul Mendez Patarroyo²⁶, Antonio iglesias Gamarra²⁴, Andres Zuniga Vera²⁷, Olga-Lidia Vera-Lastra²⁸, Mario Perez Cristobal²⁹, Eduardo Martin-Nares³⁰, Luis M Amezcua-Guerra³¹, Yelitza Gonzalez-Bello³², Octavio Gonzalez Enriquez³³, Dionico Galarzo-Delgado³⁴, Carolina Vazquez³⁵, Marcelo barrios³⁶, Magaly Alba Linares³⁷, Cristina Reategui³⁸, Ana Quiroz-Alva³⁹, Teresandris Polanco Mora⁴⁰, Carina Pizzarossa⁴¹, Martin Rebella⁴², Maria Crespo⁴³, Alvaro Danza⁴⁴, Eloisa Silva Dutra de Oliveira Bonfa⁴⁵, Graciela Alarcón⁴⁶, Federico Zazzetti⁴⁷, Ashley Orillion⁴⁸, Guillermo Pons-Estel⁴⁹ and Urbano Sbarigia⁵⁰ ¹GO-CREAR, Rosario, Santa Fe, Argentina, ²Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ⁴Instituto de Investigaciones Teóricas y Aplicadas. Facultad de Ciencias Económicas y Estadistica. Universidad Nacional de Rosario, Rosario, Argentina, ⁵Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁶Hospital Italiano de Córdoba, Córdoba, Argentina, ⁷Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ⁹Hospital HIGA San Martín, San Martín, Argentina, ¹⁰Sanatorio Británico, Rosario, Argentina, ¹¹Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumáticas del Grupo Oroño, Rosario, Argentina, ¹²Hospital Padilla, San Miguel de Tucuman, Argentina, ¹³Hospital General de Agudos Dr. Ramos Mejia, Buenos Aires, Argentina, ¹⁴Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina, ¹⁵CEMIC, Galvan, Argentina, ¹⁶Universidade Federal de Goiás, Goiana, Brazil, ¹⁷Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ¹⁸Universidad Federal de Pernambuco, Recife, Brazil, ¹⁹Hospital Universitario Pedro Ernesto, UERJ, Rio de Janiero, Brazil, ²⁰Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²¹Universidad Federal São Paulo, São Paulo, Brazil, ²²Hospital del Salvador, Providencia, Chile, ²³Universidad San Sebastián, Santiago de Chile, Chile, ²⁴Clínica de la Costa Ltda., Barranquilla, Colombia, ²⁵Fundación Valle del Lili, Calí, Colombia, ²⁶Fundación Santa Fe, Bogotá, Colombia, ²⁷Hospital Luis Vernaza, Guayaquil, Ecuador, ²⁸Centro Médico La Raza, Ciudad de México, Mexico, ²⁹Centro Médico Nacional Siglo XXI, Ciudad de México, Mexico, ³⁰Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ³¹Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, ³²Centro de Estudios de investigación Básica y Clínica S.C, Jalisco, Mexico, ³³Hospital Central Dr. Ignacio Morones Prieto, San Luis, Mexico, ³⁴Hospital Universitario "Dr. José Eleuterio Gonzalez", Monterrey, Mexico, ³⁵Hospital de Clínicas I, Montevideo, Uruguay, ³⁶Hospital de Clínicas II, Montevideo, Uruguay, ³⁷Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, ³⁸Hospital Nacional Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ³⁹Hospital Cayetano Heredia, San Martín de Porres District, Peru, ⁴⁰Hospital Docente Padre Billini, Santo Domingo, Dominican Republic, ⁴¹Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, ⁴²Departamento de Medicina, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, ⁴³Hospital Señor del Milagro, Salta, Argentina, ⁴⁴Grupo de Investigacion de EAIS y Reumatológicas, A Coruña, Spain, ⁴⁵Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁴⁶The University of Alabama at Birmingham, Oakland, ⁴⁷Janssen Medical Affairs Global Services, LLC, Buenos Aires, Argentina, ⁴⁸Janssen, Horsham, PA, ⁴⁹CREAR, Rosario, Argentina, ⁵⁰Johnson & Johnson, Beerse, Belgium
Background/Purpose: Clinically evident kidney disease eventually occurs in up to one-half of SLE patients. The aim of this study is to describe sociodemographic, clinical, serological…
Abstract Number: 1459 • ACR Convergence 2022
Evolution of Subjective Cognitive Impairment Overtime in SLE Patients: Bayesian Longitudinal Item Response Theory Modelling
Michelle Barraclough¹, Juan Pablo Diaz-Martinez², Andrea Knight³, Kathleen Bingham⁴, Jiandong Su², Mahta Kakvan⁵, Carolina Munoz², Maria Carmela Tartaglia⁶, Leslet Ruttan⁷, Joan Wither⁵, May Choi⁸, Nicole Anderson⁹, Dennisse Bonilla², Simone Appenzeller¹⁰, Ben Parker¹¹, Patricia Katz¹², Dorcas Beaton¹³, Robin Green⁷, Ian N. Bruce¹⁴ and Zahi Touma², ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁴Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ⁶University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, ⁷University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁸Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁹Schroeder Arthritis Institute, Krembil Research Institute and University Health Network, University of Toronto, Toronto, ON, Canada, ¹⁰Unicamp, Campinas, São Paulo, Brazil, ¹¹Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ¹²UCSF, San Rafael, CA, ¹³Institute for Work & Health, Toronto, ON, Canada, ¹⁴Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Subjective cognitive impairment (SCI) is a significant problem in SLE and there are a lack of studies assessing change over time in SCI. The…
Abstract Number: 1400 • ACR Convergence 2022
Machine Learning Identifies Molecular Phenotypes That Predict Incident Cardiovascular Disease in Patients with Rheumatoid Arthritis
Tate Johnson¹, Rebekah Gundry², Merry Lindsey², Punyasha Roul³, Yangyuna Yang², Joshua Baker⁴, Brian Sauer⁵, Grant Cannon⁶, Geoffrey Thiele², Ted Mikuls⁷ and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³UNMC, Omaha, NE, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Retired, Salt Lake City, UT, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cardiovascular disease (CVD) remains the leading cause of death in patients with rheumatoid arthritis (RA). General population CVD risk calculators underestimate risk in RA,…
Abstract Number: 1350 • ACR Convergence 2022
A Prospective Study on Pain Associated with Injection of Needles: PAIN Study
Chay Bae¹, Eugenia Chen¹ and Maida Wong², ¹Rheumatology, University of California, Irvine School of Medicine, Irvine, CA, ²Rheumatology, VA Long Beach Healthcare System, Long Beach, CA
Background/Purpose: Joint pain is a common issue amongst patients. In the appropriate clinical setting, joint injections or aspirations may benefit the patient. Pain, however, is…
Abstract Number: 1205 • ACR Convergence 2022
Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines Against COVID-19 Infection Among Patients with Systemic Autoimmune Rheumatic Diseases
Claire Cook¹, Naomi Patel², Xiaoqing Fu¹, Xiaosong Wang³, Yumeko Kawano³, Kathleen Vanni³, Grace Qian³, Emily Banasiak³, Emily Kowalski³, Hyon Choi⁴, yuqing zhang⁵, Jeffrey Sparks⁶ and Zachary Wallace¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Sale Creek, TN, ³Brigham and Women's Hospital, Boston, MA, ⁴MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁵Massachusetts General Hospital, Quincy, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARDs) on immunomodulatory medications may be at particular risk for COVID-19 breakthrough infection given uncertain immune response to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].